LRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Stride, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Stride, Inc. (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, both dates inclusive (the "Class Period†), have until January 12, 2026 to seek appointment as lead plaintiff of the Stride class action laws ...

Core Insights - Mersana is under investigation for potential breaches of fiduciary duty related to its transaction with Day One Biopharmaceuticals [1][3] Transaction Details - Mersana shareholders will receive $25.00 per share in cash, with potential contingent value rights payments of up to $30.25 per share, leading to a total equity value of approximately $129 million at closing and a total deal value of up to approximately $285 million if all milestones are met [2] - The contingent payments are linked to clinical development, regulatory, and commercial milestones for Mersana's B7-H4-directed antibody-drug conjugate Emi-Le [2] Governance Concerns - Mersana insiders are set to receive substantial benefits from change of control arrangements, raising concerns about the fairness of the transaction [3] - The transaction agreement imposes significant penalties on Mersana for accepting competing bids, which may indicate a lack of fiduciary responsibility by the board of directors [3]

Core Viewpoint - The Telix Pharmaceuticals class action lawsuit alleges that the company and its executives made false statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain, leading to significant stock price declines following negative disclosures [4][5][6]. Company Overview - Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [3]. Allegations of the Lawsuit - The lawsuit claims that during the Class Period, Telix Pharmaceuticals materially overstated its progress in developing prostate cancer therapeutics and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures on prostate cancer therapeutics, resulting in a more than 13% drop in its stock price over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the FDA for its product TLX250-CDx, citing deficiencies in the Chemistry, Manufacturing, and Controls package, which led to a more than 21% decline in its stock price over two trading sessions [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Telix Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [8].

Core Viewpoint - The Ademi Firm is investigating Gulf Island for potential breaches of fiduciary duty and other legal violations related to its transaction with IES Holdings Inc, which involves a cash payment of $12.00 per share for Gulf Island shareholders, totaling approximately $192 million [1][2]. Group 1: Transaction Details - Gulf Island shareholders will receive $12.00 per share in cash, equating to an aggregate equity value of around $192 million [2]. - Approximately 20% of Gulf Island's outstanding shares are held by certain shareholders who have entered voting agreements to support the transaction, while IES, owning about 3.5% of Gulf Island's shares, has also agreed to vote in favor of the deal [2]. Group 2: Board Conduct and Limitations - The transaction agreement imposes significant penalties on Gulf Island if it accepts competing bids, which raises concerns about the board's conduct and whether they are fulfilling their fiduciary duties to all shareholders [3]. - The investigation focuses on the Gulf Island board of directors' actions in relation to the transaction and their responsibilities towards shareholders [3]. Group 3: Legal Context - The Ademi Firm specializes in shareholder litigation concerning buyouts, mergers, and individual shareholder rights, indicating a broader context of legal scrutiny in similar transactions [4].

Core Viewpoint - The Ademi Firm is investigating Evoke for potential breaches of fiduciary duty and other legal violations related to its recent transaction, which involves a cash tender offer for shareholders at $11.00 per share [2]. Group 1: Transaction Details - Evoke shareholders are set to receive $11.00 per share in cash through a tender offer [2]. - The transaction includes substantial benefits for Evoke insiders as part of change of control arrangements [2]. - The transaction agreement imposes significant penalties on Evoke for accepting competing bids, which may limit shareholder options [2]. Group 2: Investigation Focus - The investigation by the Ademi Firm centers on the conduct of Evoke's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [2].

Core Viewpoint - The Ademi Firm is investigating Vital Energy for potential breaches of fiduciary duty and other legal violations related to its transaction with Crescent Energy Company [1][3]. Group 1: Transaction Details - Shareholders of Vital Energy will receive 1.9062 shares of Crescent Class A common stock for each share of Vital Energy common stock, resulting in Crescent shareholders owning approximately 77% of the combined company and Vital Energy shareholders owning about 23% on a fully diluted basis [2]. - Vital Energy insiders are set to receive substantial benefits as part of change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes significant penalties on Vital Energy if it accepts a competing bid, which may limit competing transactions unreasonably [3]. - The investigation will assess whether the Vital Energy board of directors is fulfilling their fiduciary duties to all shareholders [3].

Core Viewpoint - The Ademi Firm is investigating Civitas for potential breaches of fiduciary duty and other legal violations related to its transaction with SM Energy, which involves a share exchange agreement [1][3]. Group 1: Transaction Details - Each Civitas share will be exchanged for 1.45 shares of SM Energy common stock, resulting in SM Energy stockholders owning approximately 48% and Civitas stockholders owning approximately 52% of the combined company on a fully diluted basis [2]. - Civitas insiders are set to receive substantial benefits as part of the change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes significant penalties on Civitas for accepting competing bids, which raises concerns about the board's fulfillment of fiduciary duties to all shareholders [3].

Core Insights - The Ademi Firm is investigating Jamf for potential breaches of fiduciary duty and other legal violations related to its transaction with Francisco Partners [1][2] - Jamf shareholders are set to receive $13.05 per share in cash, which values the company at approximately $2.2 billion [2] - The transaction agreement includes provisions that significantly limit competing offers for Jamf, imposing penalties if a competing bid is accepted [2] Company and Transaction Details - Jamf insiders are expected to receive substantial benefits as part of the change of control arrangements [2] - The investigation focuses on whether the Jamf board of directors is fulfilling their fiduciary duties to all shareholders amidst the transaction [2]

Core Viewpoint - The Ademi Firm is investigating Olympic Steel for potential breaches of fiduciary duty and other legal violations related to its transaction with Ryerson, which involves a share exchange that may not be in the best interest of shareholders [1][3]. Group 1: Transaction Details - Olympic Steel shareholders will receive 1.7105 Ryerson shares for each Olympic Steel share, resulting in them owning approximately 37% of the combined entity [2]. - Olympic Steel insiders are set to receive substantial benefits as part of change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes significant penalties on Olympic Steel if it accepts competing bids, which raises concerns about the board's fulfillment of fiduciary duties to all shareholders [3].

Core Insights - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) [1] - The investigation is based on a federal securities lawsuit alleging that insiders provided misleading information regarding the company's lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy [1] - The lawsuit claims that while Capricor communicated its ability to obtain a Biologics License Application (BLA) from the FDA, it also concealed adverse facts related to the safety and efficacy data from its Phase 2 HOPE-2 trial [1] Company Investigation - The investigation focuses on whether Capricor's management misled investors about the prospects of deramiocel [1] - The allegations include the dissemination of false statements and the concealment of material adverse facts regarding the drug's four-year safety and efficacy data [1] Shareholder Actions - Shareholders who purchased CAPR shares prior to October 9, 2024, are encouraged to contact Kuehn Law for potential legal action [2] - Kuehn Law offers to cover all case costs and does not charge its investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [3]